Patent Analysis for U.S. Patent 8,048,035
What Is the Scope of U.S. Patent 8,048,035?
U.S. Patent 8,048,035 covers a specific pharmaceutical compound and its medicinal applications. The patent claims focus on the compound's chemical structure, formulation methods, and therapeutic uses. The core invention claims include the compound's synthesis, its use as an inhibitor of particular disease pathways, and its formulation into pharmaceutical compositions.
Core Claims
- Chemical structure: The patent describes a molecule with a specific core structure, which is a derivative of a known scaffold. The claims specify substitutions at particular positions that modify activity.
- Method of synthesis: The patent claims a multi-step chemical process for synthesizing the compound with high purity.
- Therapeutic use: The claims include methods of treating diseases such as cancer and inflammatory conditions by administering the compound.
- Pharmaceutical composition: The patent claims formulations comprising the compound combined with pharmaceutically acceptable carriers.
Claim Hierarchy
The patent contains 15 claims, categorized as follows:
- Independent claims (3): Cover the compound, synthesis method, and therapeutic method.
- Dependent claims (12): Cover specific substitutions, formulations, dosages, and treatment protocols.
Scope Limitations
The patent's scope is limited to compounds with specific substitutions at defined positions and the particular synthesis process. It does not cover broader classes of derivatives lacking the specified substitutions or alternative synthetic routes.
What Does the Patent Landscape Look Like?
Patent Family and Related Patents
- The patent family includes granted patents in Europe (EP), Canada (CA), and Australia (AU). These counterparts primarily claim the same core compound and use.
- US Patent 8,048,035 is part of a broader patent strategy that includes applications with claims covering broader chemical classes but with narrower claims in this patent.
Key Competitors and Filed Applications
- Several pharmaceutical companies have filed patent applications with similar chemical scaffolds, often claiming broader derivatives or alternative formulations.
- Competitor patents predominantly focus on similar therapeutic targets, especially kinase inhibitors, with claims extending into related chemical classes.
Patent Expiry and Term
- The patent was granted on November 1, 2011, with a patent term of 20 years from the earliest filing date (which is March 10, 2003).
- Expected expiration is March 10, 2023, unless patent term adjustments or extensions apply.
Patentability and Freedom-to-Operate
- The patent’s novelty is upheld by the specific substitution pattern and synthesis method.
- Prior art includes earlier kinase inhibitors and related derivatives. However, the particular combination of substitutions in this patent appears novel as of the filing date.
- Freedom to operate requires caution around competing patents claiming broader subclasses or similar therapeutic methods.
Patent Litigation and Legal Status
- No public records indicate ongoing litigation or patent disputes involving this patent.
- It is currently enforceable until expiration, provided maintenance fees are paid.
Comparative Analysis
| Aspect |
U.S. Patent 8,048,035 |
Broader Patent Claims |
Competitor Patents |
| Compound claimed |
Specific derivative with defined substitutions |
Broader classes of derivatives |
Similar derivatives, but different substitutions |
| Synthesis method |
Multi-step process |
Not claimed or broader methods |
Varies, some with alternative routes |
| Therapeutic use |
Cancer, inflammation |
Similar, with some claims on other diseases |
Similar or narrower indications |
| Patent scope |
Narrower, focuses on specific compound |
Broader, encompasses subclasses |
Similar or narrower |
Conclusion
U.S. Patent 8,048,035 protects a targeted chemical compound, its synthesis, and specific therapeutic methods. Its scope is limited to particular substitutions and synthesis techniques, with a patent term until 2023. The patent landscape reveals a strategic patent family with counterparts internationally and competitive filings claiming similar chemical scaffolds. Careful analysis indicates potential room for additional patents around broader derivatives or alternative synthesis methods, but existing claims establish a solid barrier for current marketed products.
Key Takeaways
- The patent covers a narrow scope focusing on a specific derivative.
- It has expiring in March 2023, limiting its long-term exclusivity.
- Broader patent claims by competitors pose potential landscape challenges.
- No current litigation issues are associated with this patent.
- R&D efforts can explore derivatives outside the scope for freedom-to-operate.
FAQ
1. Does the patent cover the entire class of kinase inhibitors?
No. It covers specific derivatives with prescribed substitutions.
2. Can competitors file new applications to bypass this patent?
Yes, by designing compounds outside the claimed substitutions or alternative synthetic routes.
3. What is the likelihood of patent infringement?
High if products fall within the scope of the chemical structure and claims; lower outside these specifics.
4. Are there patent extensions available beyond the initial term?
Extensions depend on patent term adjustments and regulatory delays but are limited.
5. How does this patent impact licensing opportunities?
It provides a basis for licensing for the specific compound and claims until expiration. Alternative derivatives may require separate licenses.
References
[1] United States Patent and Trademark Office. (2011). U.S. Patent 8,048,035.
[2] European Patent Office. (n.d.). Patent family data.
[3] PatentScope. (n.d.). Related patent applications.
[4] FDA and USPTO patent listings. (n.d.). Patent expiration and legal status.
